Eric K Soule1, Andrew D Plunk2, Paul T Harrell2, Rashelle B Hayes3, Kathryn C Edwards4. 1. Department of Health Education and Promotion, East Carolina University, Greenville, NC. 2. Department of Pediatrics, Eastern Virginia Medical School, Norfolk, VA. 3. Department of Psychiatry, Virginia Commonwealth University, Richmond, VA. 4. Westat, Behavioral Health Group, Rockville, MD.
Abstract
INTRODUCTION: Electronic cigarette (ECIG) use and changes in cigarette smoking status may be influenced by self-reported reasons for using ECIGs. METHODS: We analyzed adult current and former cigarette smokers who were also current or former ECIG users at wave 1 (n = 3044) using wave 1 and wave 2 Population Assessment of Tobacco and Health Study data (2013-2015). Prevalence of reporting 13 reasons for ECIG use at wave 1 was examined and weighted logistic regressions were conducted predicting smoking status changes from wave 1 to wave 2. RESULTS: Reasons for ECIG use ranged from 18.1% (people in the media or public figures use them) to 82.5% (they might be less harmful to people around me than cigarettes). From wave 1 to wave 2, 27.2% of former smokers (n = 249) became current smokers and 11.6% of current smokers (n = 246) became former smokers. Among wave 1 former smokers, using ECIGs because of the availability of flavors (AOR = 0.57, 95% CI = 0.39-0.85) or because they don't smell (AOR = 0.64, 95% CI = 0.42-0.97) was associated with lower odds of relapse to smoking, but using ECIGs because using them helps people quit smoking (AOR = 1.55, 95% CI = 1.01-2.38) was associated with greater odds of relapse. Among wave 1 current smokers, using ECIGs because they can be used where smoking is not allowed (AOR = 0.56, 95% CI = 0.38-0.85) was associated with reduced odds of quitting cigarettes. CONCLUSIONS: Some reasons for ECIG use are associated with changes in self-reported smoking status. Researchers should examine ECIG user characteristics when assessing associations between ECIG use and smoking status transitions. IMPLICATIONS: Given that certain reasons for ECIG use, such as using ECIGs in locations are where smoking is not allowed, may inhibit smoking reduction, policies may be developed to prevent ECIG use in locations where smoking is banned. In addition, because certain reasons for ECIG use may aid in relapse prevention, such as availability of desired flavors, efforts should be made to identify ECIG device characteristics that are appealing to smokers but not youth or nontobacco users. These results provide support for future research on reasons for ECIG use to inform regulatory policies.
INTRODUCTION: Electronic cigarette (ECIG) use and changes in cigarette smoking status may be influenced by self-reported reasons for using ECIGs. METHODS: We analyzed adult current and former cigarette smokers who were also current or former ECIG users at wave 1 (n = 3044) using wave 1 and wave 2 Population Assessment of Tobacco and Health Study data (2013-2015). Prevalence of reporting 13 reasons for ECIG use at wave 1 was examined and weighted logistic regressions were conducted predicting smoking status changes from wave 1 to wave 2. RESULTS: Reasons for ECIG use ranged from 18.1% (people in the media or public figures use them) to 82.5% (they might be less harmful to people around me than cigarettes). From wave 1 to wave 2, 27.2% of former smokers (n = 249) became current smokers and 11.6% of current smokers (n = 246) became former smokers. Among wave 1 former smokers, using ECIGs because of the availability of flavors (AOR = 0.57, 95% CI = 0.39-0.85) or because they don't smell (AOR = 0.64, 95% CI = 0.42-0.97) was associated with lower odds of relapse to smoking, but using ECIGs because using them helps people quit smoking (AOR = 1.55, 95% CI = 1.01-2.38) was associated with greater odds of relapse. Among wave 1 current smokers, using ECIGs because they can be used where smoking is not allowed (AOR = 0.56, 95% CI = 0.38-0.85) was associated with reduced odds of quitting cigarettes. CONCLUSIONS: Some reasons for ECIG use are associated with changes in self-reported smoking status. Researchers should examine ECIG user characteristics when assessing associations between ECIG use and smoking status transitions. IMPLICATIONS: Given that certain reasons for ECIG use, such as using ECIGs in locations are where smoking is not allowed, may inhibit smoking reduction, policies may be developed to prevent ECIG use in locations where smoking is banned. In addition, because certain reasons for ECIG use may aid in relapse prevention, such as availability of desired flavors, efforts should be made to identify ECIG device characteristics that are appealing to smokers but not youth or nontobacco users. These results provide support for future research on reasons for ECIG use to inform regulatory policies.
Authors: M L Saddleson; L T Kozlowski; G A Giovino; L W Hawk; J M Murphy; M G MacLean; M L Goniewicz; G G Homish; B H Wrotniak; M C Mahoney Journal: Drug Alcohol Depend Date: 2015-01-24 Impact factor: 4.492
Authors: Ahmad El-Hellani; Rola Salman; Rachel El-Hage; Soha Talih; Nathalie Malek; Rima Baalbaki; Nareg Karaoghlanian; Rima Nakkash; Alan Shihadeh; Najat A Saliba Journal: Nicotine Tob Res Date: 2018-01-05 Impact factor: 4.244
Authors: Theodore L Wagener; Evan L Floyd; Irina Stepanov; Leslie M Driskill; Summer G Frank; Ellen Meier; Eleanor L Leavens; Alayna P Tackett; Neil Molina; Lurdes Queimado Journal: Tob Control Date: 2016-10-11 Impact factor: 7.552
Authors: Ralph S Caraballo; Paul R Shafer; Deesha Patel; Kevin C Davis; Timothy A McAfee Journal: Prev Chronic Dis Date: 2017-04-13 Impact factor: 2.830
Authors: Adam M Leventhal; Nicholas I Goldenson; Jessica L Barrington-Trimis; Raina D Pang; Matthew G Kirkpatrick Journal: Drug Alcohol Depend Date: 2019-08-01 Impact factor: 4.492
Authors: Afaf F Moustafa; Daniel Rodriguez; Stephen H Pianin; Shannon M Testa; Janet E Audrain-McGovern Journal: Am J Prev Med Date: 2022-03-29 Impact factor: 6.604
Authors: Daniel Owusu; Jidong Huang; Scott R Weaver; Terry F Pechacek; David L Ashley; Pratibha Nayak; Michael P Eriksen Journal: Prev Med Rep Date: 2019-10-25